Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation

Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation

Oncogenic mutations in two isocitrate dehydrogenase (IDH)-encoding genes (IDH1 and IDH2) have been identified in acute myelogenous leukemia, low-grade glioma, and secondary glioblastoma (GBM). Our in silico and wet-bench analyses indicate that non-mutated IDH1 mRNA and protein are commonly overexpre...

Full description

Bibliographic Details
Main Authors: Andrea E. Calvert, Alexandra Chalastanis, Yongfei Wu, Lisa A. Hurley, Fotini M. Kouri, Yingtao Bi, Maureen Kachman, Jasmine L. May, Elizabeth Bartom, Youjia Hua, Rama K. Mishra, Gary E. Schiltz, Oleksii Dubrovskyi, Andrew P. Mazar, Marcus E. Peter, Hongwu Zheng, C. David James, Charles F. Burant, Navdeep S. Chandel, Ramana V. Davuluri, Craig Horbinski, Alexander H. Stegh
Format: Article
Language:English
Published: Elsevier 2017-05-01
Series:Cell Reports
Subjects:
wild-type IDH1
GBM
metabolism
differentiation
NADPH
lipids
reactive oxygen species (ROS)
EGFR
targeted therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124717306393

Internet

http://www.sciencedirect.com/science/article/pii/S2211124717306393

Similar Items